Total cholesterol blood test
Total cholesterol. Also called: Cholesterol, total, Serum cholesterol, TC
Total cholesterol is all the cholesterol in your blood, carried in LDL, HDL and triglyceride-rich particles. For adults, below 200 mg/dL is desirable and 240 or higher is high. Read it with LDL and HDL, which explain where it comes from.
One of the four values on a standard Lipid Panel. The panel page also covers the advanced tests, ApoB and Lp(a).
At a glance
| What it measures | All the cholesterol in your blood: the cholesterol carried in LDL, HDL and the triglyceride-rich particles, added together. |
|---|---|
| Sample | Serum or plasma. Fasting is not needed when it is part of a lipid panel. |
| Adult categories | Desirable below 200 mg/dL; borderline high 200-239; high 240 or higher (NCEP ATP III). |
| Peptides that move it | Lowered modestly by Semaglutide, Tirzepatide, Liraglutide and Tesamorelin; raised by GnRH drugs such as Leuprolide and Goserelin. |
| Lab code | LOINC 2093-3 (Labcorp 001065, Quest 334) |
What is Total cholesterol?
Total cholesterol is the sum of the cholesterol in every lipoprotein in the blood: LDL, HDL and the triglyceride-rich particles (VLDL and their partly broken-down remnants). A standard lipid panel measures total cholesterol, HDL and triglycerides directly and calculates the rest. Total cholesterol minus HDL gives non-HDL cholesterol, the cholesterol in all the particles that can build up in artery walls.
How it is made and regulated
Where it is made
LDL is removed from the blood through the LDL-receptor pathway that Brown and Goldstein described. Mutations that weaken LDL clearance, in the LDL receptor or APOB genes and in a third gene, PCSK9, cause autosomal dominant hypercholesterolemia, with high cholesterol from birth.
What controls it
Diet, weight and genes set the level. NCEP ATP III bases prevention on less saturated fat and dietary cholesterol, more physical activity and weight control. It lists diabetes, hypothyroidism, obstructive liver disease, chronic kidney failure and drugs such as progestins, anabolic steroids and corticosteroids as secondary causes of abnormal lipids to rule out before treatment.
How it travels in the blood
The test measures the cholesterol inside all lipoprotein particles together. Labs measure total cholesterol enzymatically in serum or plasma; Labcorp and Quest run it alone or as part of the lipid panel.
How long it lasts
Total cholesterol changes slowly. A normal meal moves it down by only about 8 mg/dL at most, so a non-fasting result is usable. The 2026 ACC/AHA guideline reassesses lipids after starting or changing treatment, looking at both the percentage fall and the level reached. The 2018 guideline it replaced rechecked at 4 to 12 weeks.
What it does
Framingham scores use total cholesterol to estimate 10-year heart risk because its database is larger than LDL's, but ATP III makes LDL the main treatment target. In Framingham adults aged 49 to 82, total cholesterol on its own was not associated with heart disease, while HDL and LDL were.
Reference ranges
Total cholesterol is read against risk categories rather than a population range. Labcorp prints 100-199 mg/dL; Quest prints below 200 for adults and below 170 under age 20; ATP III sets the desirable, borderline and high categories.
Labcorp (test 303756)
| Group | Range (mg/dL) |
|---|---|
| Adults (sample reports for women aged 31 and 64) | 100-199 |
Values above 199 are flagged high; values below 100 are flagged low.
Quest Diagnostics (test 334)
| Group | Range (mg/dL) |
|---|---|
| 20 years and older | <200 |
Children and teens
| Group | Range (mg/dL) |
|---|---|
| Under 20 years | <170 |
Read from Quest's test directory for the East service area.
NCEP Adult Treatment Panel III (NHLBI)
| Group | Range (mg/dL) |
|---|---|
| Desirable | <200 |
| Borderline high | 200-239 |
| High | 240 or higher |
Adult categories from ATP III Table 2.
The same total can hide very different LDL and HDL values, so read it with the rest of the lipid panel.
Units: Labs outside the US report cholesterol in mmol/L. Divide mg/dL by 38.6 to convert, the factor used in the European lipid consensus: 200 mg/dL is about 5.2 mmol/L. [10]
What raises it
| Factor | How | How much |
|---|---|---|
| Saturated fat and dietary cholesterolNutrition | ATP III's first lifestyle step is to cut saturated fat and cholesterol to lower population cholesterol. | No published magnitude [3] |
| Hypothyroidism, obstructive liver disease, chronic kidney failure, diabetesCondition | Listed by ATP III as secondary causes of abnormal lipids to exclude before treatment. | No published magnitude [3] |
| Progestins, anabolic steroids, corticosteroidsMedication | ATP III lists these as drugs that raise LDL and lower HDL. | No published magnitude [3] |
| Inherited high cholesterol (LDLR, APOB or PCSK9 mutations)Condition | Defects in LDL clearance raise LDL and total cholesterol from birth; PCSK9 mutations are a third cause. | No published magnitude [6] [7] |
| GnRH agonists (Leuprolide, Goserelin)Peptide | Suppressing sex hormones shifts lipids upward; the labels record higher cholesterol. | No published magnitude [16] [17] |
What lowers it
| Factor | How | How much |
|---|---|---|
| StatinsMedication | Statins lower LDL, one of the parts that make up total cholesterol. | High-intensity statins typically lower LDL by 50% or more [7] |
| Weight loss with GLP-1 drugsPeptide | Tirzepatide, Semaglutide and Liraglutide lowered total cholesterol slightly in their obesity trials. | Up to -6.3% from baseline on tirzepatide 15 mg [18] [19] [20] |
| Recent mealPhysiology | Total cholesterol is slightly lower after eating. | Largest average fall about 8 mg/dL [10] |
Peptides that affect Total cholesterol
How each peptide in our library changes total cholesterol, from FDA label tables and trials. No study has measured total cholesterol after dosing CJC-1295, Ipamorelin, HGH Fragment 176-191 or AOD-9604; a PubMed search for each peptide with cholesterol, triglycerides or lipids finds no human data (the only AOD-9604 lipid paper is a mouse study of fat loss, not blood lipids).
| Peptide | Effect on Total cholesterol | Size of effect | Evidence |
|---|---|---|---|
| Dulaglutide | Lowers | No figure in the abstract: in adolescents with thalassaemia-related diabetes, total cholesterol fell significantly on dulaglutide vs baseline and vs insulin over 24 weeksOne small trial in a specific population; dulaglutide labels report no lipid table. [21] | Human trials |
| Tesamorelin | Lowers | Meta-analysis of 4 randomized trials (909 people with HIV-associated lipodystrophy): total cholesterol mean difference -0.16 mmol/L vs placebo. In one trial the fall from baseline (-8 mg/dL) was maintained at 52 weeksA modest drop in people with HIV; tesamorelin was studied for visceral fat, not cholesterol. [22] [23] | Human trials |
| MK-677 (Ibutamoren) | No clear effect | Measured, no clear change: in obese men total cholesterol was not significantly changed by MK-677; in a 2-year trial in older adults there was no difference between groups in total cholesterolTwo trials, neither showing a change in total cholesterol. [24] [25] | Human trials |
| Goserelin | Raises | No total figure given: in women treated for endometriosis, the label states goserelin increased total cholesterol and LDL cholesterol during 6 months of treatmentSeen with the estrogen suppression of endometriosis treatment. [17] | FDA label |
| Leuprolide | Raises | No size given: in men with prostate cancer, hyperlipidemia (total cholesterol, LDL-cholesterol, triglycerides) was recorded in 5% or more of patients; the label warns that GnRH agonists may cause hyperlipidemia and asks for lipid monitoringLowering sex hormones shifts lipids upward; the label recommends checking them. [16] | FDA label |
| Liraglutide | Lowers | Saxenda 3 mg (Study 1, adults without diabetes): total cholesterol -3.2% vs -0.9% on placebo; relative difference -2.3%A small fall in the weight-management trial. [20] | FDA label |
| Semaglutide | Lowers | Wegovy 2.4 mg, 68 weeks (adults with obesity or overweight): total cholesterol -3.3% vs +0.1% on placebo; relative difference -3.3%A small fall alongside weight loss; triglycerides moved much more than cholesterol. [19] | FDA label |
| Tirzepatide | Lowers | Zepbound 15 mg, 72 weeks (Study 1): total cholesterol -6.3% vs -1.8% on placebo; relative difference -4.6%A modest, dose-related fall in the obesity trial. [18] | FDA label |
What high or low results can mean
A high result
240 mg/dL or higher is high and 200-239 borderline high. Because total cholesterol mixes LDL, HDL and triglyceride-rich particles, the next step is to look at LDL, HDL and non-HDL cholesterol.
- High LDL (diet, genes, low thyroid)
- High HDL, which also raises the total
- Kidney or liver disease
- Drugs such as corticosteroids or GnRH agonists
A low result
Below 200 mg/dL is the desirable range. Labcorp flags results below 100 mg/dL as low.
- Cholesterol-lowering treatment
- Low dietary fat intake
How the test works
| Sample | Serum (preferred) or plasma, 1 mL at Labcorp. |
|---|---|
| Fasting | As part of a lipid panel no fasting is needed at Labcorp or Quest. The European Atherosclerosis Society and EFLM recommend routine non-fasting lipid profiles: after normal meals, the largest average changes are +26 mg/dL for triglycerides and -8 mg/dL for total and LDL cholesterol, while HDL does not change. They suggest a fasting sample when non-fasting triglycerides are above 440 mg/dL. |
| Timing | ATP III recommends a lipid profile every 5 years from age 20. If the sample is non-fasting and total cholesterol is 200 mg/dL or higher, it asks for a follow-up profile. |
| Lab differences | Enzymatic assay at Labcorp; spectrophotometry at Quest. |
| Retesting | The 2026 ACC/AHA guideline reassesses lipids after starting or changing treatment, looking at both the percentage fall and the level reached. The 2018 guideline it replaced rechecked at 4 to 12 weeks, then every 3 to 12 months as needed. |
| Labcorp order code | 001065: Cholesterol, Total |
| Labcorp order code | 303756: Lipid Panel |
| Quest Diagnostics order code | 334: Cholesterol, Total |
| Quest Diagnostics order code | 7600: Lipid Panel, Standard |
| LOINC codes |
|
History
Total cholesterol was the first lipid tied to heart disease; later work showed LDL and HDL split the risk in opposite directions.
- 1977The Framingham Study reports that, at older ages, HDL predicts heart disease and total cholesterol on its own does not. [13]
- 1986Brown and Goldstein describe the LDL-receptor pathway for cholesterol homeostasis. [5]
- 2001NCEP ATP III sets the desirable, borderline and high categories still printed on US reports. [3] [4]
- 2003Mutations in PCSK9 are shown to cause autosomal dominant hypercholesterolemia. [6]
FAQ
What is a normal total cholesterol?
For adults, below 200 mg/dL is desirable, 200-239 borderline high and 240 or higher high. Labcorp prints 100-199 mg/dL; Quest prints below 200 for adults and below 170 under 20.
Do I need to fast?
Not when it is part of a lipid panel. A normal meal lowers total cholesterol by about 8 mg/dL at most.
Is high total cholesterol always bad?
Not necessarily. It includes HDL, so a high HDL can push the total up. LDL and non-HDL cholesterol are better guides to risk.
What is non-HDL cholesterol?
Total cholesterol minus HDL: the cholesterol in LDL and the triglyceride-rich particles. ATP III uses it as a second target when triglycerides are 200 mg/dL or higher.
Sources: [3]
Why do risk calculators use total cholesterol?
Framingham risk scoring uses total cholesterol because its database is larger than LDL's, even though LDL is the main treatment target.
Sources: [3]
How often should cholesterol be checked?
ATP III recommends a lipid profile every 5 years from age 20. On treatment, the 2026 ACC/AHA guideline reassesses after every change; the 2018 guideline it replaced rechecked at 4 to 12 weeks, then every 3 to 12 months.
Which conditions raise cholesterol?
ATP III lists diabetes, hypothyroidism, obstructive liver disease and chronic kidney failure as secondary causes, along with drugs such as progestins, anabolic steroids and corticosteroids.
Sources: [3]
Do GLP-1 drugs lower cholesterol?
Slightly. In their obesity trials total cholesterol fell 6.3% on Tirzepatide 15 mg (vs 1.8% on placebo), 3.3% on Semaglutide 2.4 mg and 3.2% on Liraglutide 3 mg.
Can peptides raise cholesterol?
GnRH agonists can. The Leuprolide label records hyperlipidemia in 5% or more of men with prostate cancer, and Goserelin raised total and LDL cholesterol in women treated for endometriosis.
What do I convert mmol/L to mg/dL with?
Multiply mmol/L by 38.6 for cholesterol (divide mg/dL by 38.6 to go the other way). 200 mg/dL is about 5.2 mmol/L.
Sources: [10]
References
- Labcorp. Test 303756: Lipid Panel. Components, specimen, patient preparation and LOINC map. labcorp.com/tests/303756/lipid-panel
- Quest Diagnostics. Test 7600: Lipid Panel, Standard. Test directory: components, patient preparation, methodology and age- and sex-specific reference ranges. testdirectory.questdiagnostics.com/test/test-detail/7600/lipid-panel-standard?cc=PHP
- National Cholesterol Education Program. Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Executive Summary. NIH Publication No. 01-3670. National Heart, Lung, and Blood Institute; 2001. Table 2 (LDL, total and HDL cholesterol classification), triglyceride classification and Table 8 (metabolic syndrome). nhlbi.nih.gov/files/docs/guidelines/atp3xsum.pdf
- Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-97. PMID 11368702
- Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science. 1986;232(4746):34-47. PMID 3513311
- Abifadel M, Varret M, Rabès JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34(2):154-6. PMID 12730697
- Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082-e1143. PMID 30586774
- Labcorp. Test 001065: Cholesterol, Total. Methodology, specimen and LOINC map. labcorp.com/tests/001065/cholesterol-total
- Quest Diagnostics. Test 334: Cholesterol, Total. Test directory: methodology, patient preparation, reference range and clinical significance. testdirectory.questdiagnostics.com/test/test-detail/334/cholesterol-total?cc=PHP
- Nordestgaard BG, Langsted A, Mora S, et al. Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points-a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. Eur Heart J. 2016;37(25):1944-58. PMID 27122601
- Writing Committee Members, Blumenthal RS, Morris PB, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2026;153(17):e1154-e1276. PMID 41824552
- Sabouret P, Mafrica D, Giamundo DM, et al. The 2026 ACC/AHA Dyslipidemia Guideline: A Critical and Transatlantic Perspective on Personalized Lipid Management. Life (Basel). 2026;16(9). PMID 42795336
- Gordon T, Castelli WP, Hjortland MC, et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med. 1977;62(5):707-14. PMID 193398
- Labcorp. Sample report, test 303756 (Lipid Panel): reference intervals as printed for a 31-year-old woman (reported 06/10/2024). files.labcorp.com/testmenu-d8/sample_reports/303756.pdf
- Labcorp. Sample report, test 235010 (Lipid Panel With LDL/HDL Ratio): reference intervals as printed for a 64-year-old woman (reported 06/10/2024). files.labcorp.com/testmenu-d8/sample_reports/235010.pdf
- Lupron Depot (leuprolide acetate) 7.5 mg, 22.5 mg, 30 mg, 45 mg. FDA prescribing information: Warnings (metabolic syndrome) and laboratory abnormalities. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cbc8f94e-7330-4465-05ad-16d64493a5dd
- Zoladex (goserelin implant) 3.6 mg. FDA prescribing information: lipid changes in women treated for endometriosis. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=294b168b-6e5f-4db9-bf70-d599271458b3
- Zepbound (tirzepatide) injection. FDA prescribing information, Table 3 (cardiometabolic parameters, Studies 1 and 2). dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
- Wegovy (semaglutide) injection 2.4 mg. FDA prescribing information, Table 10 (cardiometabolic parameters, Study 2). dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
- Saxenda (liraglutide) injection 3 mg. FDA prescribing information, Table 6 (cardiometabolic parameters, Study 1). dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143
- Adly AAM, Ismail EAR, Abdel Kader MSEM, et al. Dulaglutide vs insulin in adolescents with thalassaemia-induced diabetes: effect on metabolism and atherogenesis (DIADEMA). Diabetologia. 2026;69(11):3210-3220. PMID 42618811
- Ditta AM, Naeem RM, Sami MM, et al. Efficacy and Safety of Tesamorelin in People Living With HIV (PLWH) With Lipodystrophy: A Systematic Review and Meta-Analysis. J Int Assoc Provid AIDS Care. 2026;25:23259582261475549. PMID 42538058
- Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010;95(9):4291-304. PMID 20554713
- Svensson J, Jansson JO, Ottosson M, et al. Treatment of obese subjects with the oral growth hormone secretagogue MK-677 affects serum concentrations of several lipoproteins, but not lipoprotein(a). J Clin Endocrinol Metab. 1999;84(6):2028-33. PMID 10372705
- Nass R, Pezzoli SS, Oliveri MC, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med. 2008;149(9):601-11. PMID 18981485
Educational information, not medical advice. Lab ranges and test codes were checked on October 31, 2026. Always use the range printed on your own report, and talk to a clinician about your results.